The goal of RPCI's Preclinical Imaging Resource (PIR) is to advance small animal imagingmethodology at the molecular, cellular and biosystem level. This is accomplished by facilitating developmentof novel basic science and clinical research, promoting advances in biotechnology, fostering development ofnew Pharmaceuticals and assessing in vivo drug delivery and therapeutic efficacy. The PIR currently offerscustomized magnetic resonance (MR) protocols designed to answer specific questions related to: (i) cancerdetection, (ii) tumor vascular function, (iii) therapeutic response, (iv) animal phenotyping and (v)pharmacokinetic /pharmacodynamic modeling. In addition, the Resource provides whole-body fluorescenceimaging of live animals and facilitates collaborative microPET research in conjunction with the University atBuffalo (UB).
The aim i s to provide readily available access and training to noninvasive, state-of-the-art invivo imaging technologies at an affordable cost to CCSG members. The PIR is available 24 hours/day, 7days/week.Three general types of MR services are offered: (a) instrumentation and expertise to acquire highresolution (< 50 urn2 in-plane spatial and < 100 ms temporal) heteronuclear imaging and spectroscopy data,(b) expertise and software for quantitative image analysis and (c) visualization of 2D and 3D data sets forprobing structural/functional relationships. MR instrumentation includes a 4.7 T wide bore (33 cm) magnetincorporating Bruker's Avance platform with ParaVision 4.0 OS, shielded Accustar gradients and digitalsystem electronics. The MR system represents the highest magnetic field strength scanner available within200 miles of RPCI. Recently expanded services include whole body in vivo optical and multispectralfluorescence imaging. Intravital Microscopy (IVM) using a MR compatible window chamber is also availablefor fluorescence imaging with MR validation. Data acquisition, hardcopy, display, qualitative/quantitativeanalysis and 3D renderings of digitally acquired data sets are offered as chargeback services.The Resource is used by five programs and 99% of users are CCSG members. $65,218 in CCSGsupport is requested, representing 12% of the total operating budget.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016056-32
Application #
7714431
Study Section
Subcommittee G - Education (NCI)
Project Start
2008-07-28
Project End
2013-04-30
Budget Start
2008-07-28
Budget End
2009-04-30
Support Year
32
Fiscal Year
2008
Total Cost
$54,818
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Mayor, Paul C; Eng, Kevin H; Singel, Kelly L et al. (2018) Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 141:1028-1035
Dasgupta, Subhamoy; Rajapakshe, Kimal; Zhu, Bokai et al. (2018) Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature 556:249-254
La Shu, Shin; Yang, Yunchen; Allen, Cheryl L et al. (2018) Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment. Sci Rep 8:12905
Zhang, Dingxiao; Tang, Dean G; Rycaj, Kiera (2018) Cancer stem cells: Regulation programs, immunological properties and immunotherapy. Semin Cancer Biol 52:94-106
Gabriel, Emmanuel; Attwood, Kristopher; Al-Sukhni, Eisar et al. (2018) Age-related rates of colorectal cancer and the factors associated with overall survival. J Gastrointest Oncol 9:96-110
Ma, Wen Wee; Xie, Hao; Fetterly, Gerald et al. (2018) A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Am J Clin Oncol :
Chen, George L; Carpenter, Paul A; Broady, Raewyn et al. (2018) Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant 24:373-380
Eng, Kevin H; Szender, J Brian; Etter, John Lewis et al. (2018) Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study. PLoS Genet 14:e1007194
Barger, Carter J; Zhang, Wa; Sharma, Ashok et al. (2018) Expression of the POTE gene family in human ovarian cancer. Sci Rep 8:17136
Bucsek, Mark J; Giridharan, Thejaswini; MacDonald, Cameron R et al. (2018) An overview of the role of sympathetic regulation of immune responses in infectious disease and autoimmunity. Int J Hyperthermia 34:135-143

Showing the most recent 10 out of 1555 publications